Literature DB >> 6176708

Regulation of the synthesis and release of slow-reacting substance of anaphylaxis from sensitized monkey lung.

B M Weichman, L S Hostelley, S P Bostick, R M Muccitelli, R D Krell, J G Gleason.   

Abstract

Immunological challenge of sensitized fragmented cynomolgus monkey lung with anti-human IgE (immunoglobulin E) induced the appearance of slow reacting substance of anaphylaxis (SRS-A) in the tissue and evoked the release of SRS-A into the Tyrode's supernatant. The elevation of tissue or residual SRS-A levels was maximal 2 min after anti-IgE challenge and remained at that plateau for at least 60 min. The released SRS-A, first detectable 3 to 5 min after challenge, achieved a plateau by 10 min. Both the released and residual SRS-A were similarly inactivated by soybean lipoxidase and were antagonized by FPL 55712 on the guinea-pig ileum. Isoproterenol, 5, 8, 11, 14-eicosatraynoic acid and SK & F 64398 all inhibited the anti-IgE induced elevation in residual SRS-A and blocked SRS-A release. Indomethacin stimulated both the elevation of residual SRS-A and the amount released. Removal of the Tyrode's supernatant containing 209 +/- 73 U of released SRS-A/g of tissue 20 min after anti-IgE resulted in the release of an additional 239 +/- 69 U/g; residual SRS-A levels remained at the plateau level. Incubation of the Tyrode's supernatant from challenged, but not control, tissue with fresh lung tissue caused a 90 +/- 7% inhibition of SRS-A release from the fresh tissue. Leukotriene D4 at 5 to 50 ng/ml (concentrations relevant to SRS-A release) showed a concentration-dependent inhibition of SRS-A release, but no effect on histamine release. Leukotriene C4 at 5 to 50 ng/mg failed to significantly alter the amount of SRS-A release. However, at 150 ng/ml, significant inhibition was observed which, in part, may have been produced by metabolism to leukotriene D4. These results demonstrate a potential role for LTD in regulating the amount of SRS-A released from monkey lung.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6176708

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells.

Authors:  Tracy R Daniels; Richard K Leuchter; Rafaela Quintero; Gustavo Helguera; José A Rodríguez; Otoniel Martínez-Maza; Birgit C Schultes; Christopher F Nicodemus; Manuel L Penichet
Journal:  Cancer Immunol Immunother       Date:  2011-11-30       Impact factor: 6.968

Review 2.  Pharmacological studies of pulmonary anaphylaxis in vitro: a review.

Authors:  P O Ogunbiyi; P Eyre
Journal:  Agents Actions       Date:  1985-12

3.  Endogenous leukotriene D4 formation during anaphylactic shock in the guinea pig.

Authors:  A Keppler; L Orning; K Bernström; S Hammarström
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

Review 4.  Animal models for IgE-meditated cancer immunotherapy.

Authors:  Tracy R Daniels; Otoniel Martínez-Maza; Manuel L Penichet
Journal:  Cancer Immunol Immunother       Date:  2011-12-23       Impact factor: 6.968

Review 5.  IgE immunotherapy against cancer.

Authors:  Lai Sum Leoh; Tracy R Daniels-Wells; Manuel L Penichet
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

6.  Mediators of arachidonic acid-induced contractions of indomethacin-treated guinea-pig airways: leukotrienes C4 and D4.

Authors:  J F Burka; M H Saad
Journal:  Br J Pharmacol       Date:  1984-03       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.